Skip to main content
. 2016 Aug 24;18(10):1034–1040. doi: 10.1111/dom.12734

Figure 1.

Figure 1

Hazard ratios and 95% confidence intervals (CI) for cardiovascular events and all‐cause mortality with empagliflozin (pooled) versus placebo. Cox regression analysis of all trials.